Neochem Bio Solutions Limited has filed a disclosure with the National Stock Exchange of India under Regulation 7(2) of the SEBI (Prohibition of Insider Trading) Regulations, 2015, reporting a purchase of equity shares by its promoter. The transaction was executed on July 28, 2026, and the disclosure was submitted by Hemangini Swapnil Dathia, Whole Time Director of the company.

Promoter Share Acquisition Details

Promoter Swapnil Rameshbhai Makati acquired 6,000 equity shares of Neochem Bio Solutions through an open market purchase on the NSE on July 28, 2026. The transaction was valued at ₹5,44,560. The table below summarises the key details of the transaction as disclosed in Form C under the SEBI PIT Regulations.

Change in Shareholding

Following the acquisition, Swapnil Rameshbhai Makati's total equity shareholding in Neochem Bio Solutions has increased. The table below presents the pre- and post-acquisition shareholding position.

Regulatory Compliance

The disclosure was made in accordance with Regulation 7(2)(b) of the SEBI (Prohibition of Insider Trading) Regulations, 2015, which mandates listed companies to submit continual disclosures received from promoters, members of the promoter group, and designated persons in Form C. No derivative transactions were reported in connection with this disclosure. The filing was digitally signed by Hemangini Swapnil Dathia, Whole Time Director, on July 28, 2026, from Ahmedabad.

Neochem Bio Solutions Limited reported a 32% year-on-year increase in revenue from operations to INR110.7 crore for the financial year ended March 31, 2026. Profit after tax surged 62% to INR12 crore, driven by a favorable product mix, higher capacity utilization, and operating leverage benefits. EBITDA for the year increased by 53% to INR22.6 crore, with margins expanding by 321 basis points to 20.4%.

The company’s strategic shift towards its own brand business, which now constitutes over 80% of operations compared to 75% white-label business in FY22, underpinned the profitability improvement. Total income for FY26 stood at INR113.4 crore, reflecting a 32% growth. The board attributed the strong performance to deepened customer relationships and an expanded specialty product portfolio.

Operational Performance

Neochem’s integrated manufacturing facility at Moraiya, Ahmedabad, operates with an installed capacity of 22,000 metric tons per annum. Capacity utilization improved steadily from approximately 35% in FY24 to 53% in FY26. The company noted that nearly 47% capacity headroom remains available within the existing facility, providing embedded growth potential without requiring major manufacturing capex in the near term.

Financial Highlights

The second half of the fiscal year contributed significantly, with H2 FY26 revenue from operations standing at INR64.9 crore, a 37% increase year-on-year. EBITDA for H2 was INR12.6 crores, translating to a margin of 19.4%, while PAT for the period was INR6.9 crores.

Strategic Developments

The Home and Personal Care (HPC) segment grew to contribute 14% of revenue in FY26, up from 2% in FY24. The company also commercialized its partnership with Lamoral Coatings from the Netherlands, focusing on bio-based fluorine-free water and stain repellent technology. Exports accounted for approximately 5% of revenue in FY26, with a presence across 12 countries including Bangladesh, Vietnam, and Canada.

Balance Sheet Strength

FY26 witnessed a substantial strengthening of the balance sheet, with long-term borrowings reduced to INR0.7 crore from INR14.3 crore in FY25. The debt-to-equity ratio improved significantly from 1.8 in FY25 to 0.2 in FY26. Short-term borrowings stood at INR17.1 crore, primarily comprising working capital facilities.